Toward a Proportionate Regulatory Framework for Gene Transfer: A Patient Group-Led Initiative

Abstract

Get full access to this article

View all access options for this article.

References

Arkin

L.A.

, Sondhi

, Worgall

et al. 2005. Confronting the issues of therapeutic misconception, enrollment decisions, and personal motives in genetic medicine-based clinical research studies for fatal disorders. Hum. Gene Ther., 16:1028–1036.

Churchill

L.R.

, Collins

M.L.

, King

N.M.P.

et al. 1998. Genetic research as therapy: implications of “gene therapy” for informed consent. J. Law Med. Ethics, 26:38–47.

Commission of the European Communities. 2006a. Directive 2006/17/EC of 8 February 2006 implementing Directive 2004/23/EC as regards certain technical requirements for the donation, procurement and testing of human tissues and cells. Official Journal of the European Union9/2/2006, L 38/40–L 38/52.http://eur-lex.europa.eu/LexUriServ/site/en/oj/2006/l_038/l_03820060209en00400052.pdf. 2011 January .

Commission of the European Communities. 2006b. Directive 2006/86/EC of 24 October 2006 implementing Directive 2004/23/EC as regards traceability requirements, notification of serious adverse reactions and events and certain technical requirements for the coding, processing, preservation, storage and distribution of human tissues and cells. Official Journal of the European Union25.10.2006, L 294/32–L 294/50.http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2006:294:0032:0050:EN:PDF. 2011 January .

European Commission, Enterprise and Industry Directorate General. 2009a. Detailed guidelines on good clinical practice specific to advanced therapy medicinal productsENTR/F/2/SF/dn D(2009) 35810.http://ec.europa.eu/health/files/eudralex/vol-10/2009_11_03_guideline.pdf. 2011 January .

European Commission, Enterprise and Industry Directorate General. 2009b. Assessment of the functioning of the “clinical trials directive” 2001/20/EC: Public consultation paperENTR/F/2/SF D(2009) 32674.http://ec.europa.eu/health/files/clinicaltrials/docs/2009_10_09_public-consultation-paper.pdf. 2011 January .

European Medicines Agency. 2009a. The EMEA transparency policy EMEA/232037/2009. www.ema.europa.eu/pdfs/human/transparency/23203709en.pdf. 2011 January .

European Medicines Agency. 2009b. Information on benefit–risk of medicines: patients', consumers' and healthcare professionals' expectationsEMEA/40926/2009.www.ema.europa.eu/pdfs/human/pcwp/4092609en.pdf. 2011 January .

European Medicines Agency. 2009c. ICH considerations: Oncolytic virusesEMEA/CHMP/ICH/607698/2008.www.ema.europa.eu/pdfs/human/genetherapy/60769808enfin.pdf. 2011 January .

10.

European Medicines Agency. 2009d. ICH considerations: General principles to address virus and vector sheddingEMEA/CHMP/ICH/449035/2009.www.ema.europa.eu/pdfs/human/ich/44903509en.pdf. 2011 January .

11.

European Medicines Agency, Committee for Advanced Therapies. 2010a. Scientific guideline on the minimum quality and non-clinical data for certification of advanced therapy medicinal productsEMEA/CAT/486831/2008 EMA.www.ema.europa.eu/pdfs/human/cat/48683108en.pdf. 2011 January .

12.

European Medicines Agency, Committee for Advanced Therapies. 2010b. Reflection paper on stem cell-based medicinal productsEMA/CAT/571134/2009.www.ema.europa.eu/pdfs/human/cat/57113409en.pdf. 2011 January .

13.

European Medicines Agency, Committee for Human Medicinal Products. 2007. Guideline on human cell-based medicinal productsEMEA/CHMP/410869/2006.http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003898.pdf. 2011 January .

14.

European Medicines Agency, Committee for Medicinal Products for Human Use. 2005. Guideline on development and manufacture of lentiviral vectorsCPMP/BWP/2458/2003.http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500003984.pdf. 2011 January .

15.

European Medicines Agency, Committee for Medicinal Products for Human Use. 2006. Guideline on non-clinical testing for inadvertent germline transmission of gene transfer vectorsEMEA/273974/2005.http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500003982.pdf. 2011 January .

16.

European Medicines Agency, Committee for Medicinal Products for Human Use. 2007a. Guideline on the non-clinical studies required before first clinical use of gene therapy medicinal productsEMEA/CHMP/GTWP/125459/2006.http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003743.pdf. 2011 January .

17.

European Medicines Agency, Committee for Medicinal Products for Human Use. 2007b. Guideline on scientific requirements for the environmental risk assessment of gene therapy medicinal productsCHMP/GTWP/125491/2006.http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003744.pdf. 2011 January .

18.

European Medicines Agency, Committee for Medicinal Products for Human Use. 2008a. Guideline on follow up of patients administered with gene therapy medicinal productsEMEA/CHMP/GTWP/60436/2007.http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003954.pdf. 2011 January .

19.

European Medicines Agency, Committee for Medicinal Products for Human Use. 2008b. Guideline on safety and efficacy follow-up—risk management of advanced therapy medicinal productsEMEA/149995/2008.http://www.ema.europa.eu/pdfs/human/advancedtherapies/14999508enfin.pdf. 2011 January .

20.

European Medicines Agency, Committee for Medicinal Products for Human Use. 2009a. Draft concept paper on the development of a guideline on the risk-based approach according to Annex I, Part IV of Dir. 2001/83/EC applied to ATMPsEMA/CHMP/CPWP/708420/2009.www.ema.europa.eu/pdfs/human/cpwp/70842009en.pdf. 2011 January .

21.

European Medicines Agency, Committee for Medicinal Products for Human Use. 2009b. Reflection paper: Quality, non-clinical and clinical issues relating specifically to recombinant adeno-associated viral vectorsEMEA/CHMP/GTWP/587488/2007.www.ema.europa.eu/pdfs/human/genetherapy/58748807en.pdf. 2011 January .

22.

European Medicines Agency, Committee for Medicinal Products for Human Use. 2009c. Questions and answers document on gene therapyEMA/CHMP/GTWP/212377/2008.www.ema.europa.eu/pdfs/human/genetherapy/21237708en.pdf. 2011 January .

23.

European Medicines Agency, Committee for Medicinal Products for Human Use. 2009d. Concept paper on the revision of the note for guidance on the quality, pre-clinical and clinical aspects of gene transfer medicinal productsEMA/CHMP/GTWP/BWP/234523/2009.www.ema.europa.eu/pdfs/human/genetherapy/23452309en.pdf. 2011 January .

24.

European Medicines Agency, Committee for Medicinal Products for Human Use. 2010a. multidisciplinary guidelines introduction. http://www.ema.europa.eu/htms/human/humanguidelines/multidiscipline.htm. 2011 January .

25.

European Medicines Agency, Committee for Medicinal Products for Human Use. 2010b. Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cellsEMA/CHMP/GTWP/671639/2008.www.ema.europa.eu/pdfs/human/genetherapy/67163908en.pdf. 2011 January .

26.

Goodyear

2006. Learning from the TGN1412 trial. BMJ, 332:677–678.

27.

Henderson

G.E.

, Easter

M.M.

, Zimmer

et al. 2006. Therapeutic misconception in early phase gene transfer trials. Social Sci. Med., 62:239–253.

28.

Henderson

G.E.

, Churchill

L.R.

, Davis

A.M.

et al. 2007. Clinical trials and medical care: Defining the therapeutic misconception. PLoS Med., 4:1735–1738.

29.

King

N.M.P.

2000. Defining and describing benefit appropriately in clinical trials. J. Law Med. Ethics, 28:332–343.

30.

King

N.M.P.

, Cohen-Haguenauer

2008. En route to ethical recommendations for gene transfer clinical trials. Mol. Ther., 16:432–438.

31.

King

N.M.P.

, Henderson

G.E.

, Churchill

L.R.

et al. 2005. Consent forms and the therapeutic misconception: The example of gene transfer research. IRB, 27:1–8.

32.

London

A.J.

, Kimmelman

, Emborg

M.E.

2010. Beyond access vs. protection in trials of innovative therapies. Science, 328:829–830.

33.

Office of Biotechnology Activities, National Institutes of Health. 2011. Links to GeMCRIS and the NIH Guidance on Informed Consent. http://oba.od.nih.gov/rdna/rdna.html. 2011 January 24.

34.

Schneider

C.K.

, Salmikangas

, Jilma

; for the Committee for Advanced Therapies (CAT), CAT Scientific Secretariat2010. Challenges with advanced therapy medicinal products and how to meet them. Nat. Rev. Drug Discov., 9:195–201.

35.

U.S. Food and Drug Administration. 2010. Treatment use of an investigational new drug21 CFR 312.34.http://edocket.access.gpo.gov/cfr_2003/aprqtr/pdf/21cfr312.34.pdf. 2011 January .